617 related articles for article (PubMed ID: 11322250)
1. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.
Yerly S; Denereaz N; Mermillod B; Hirschel B; Perrin L
Antivir Ther; 1996 Aug; 1(3):167-71. PubMed ID: 11322250
[TBL] [Abstract][Full Text] [Related]
2. Reverse transcriptase genotype and antiretroviral susceptibility of human immunodeficiency virus isolates from patients with advanced disease treated with didanosine: correlation with virologic response and survival.
Shepp DH; Ashraf A; Tang IT; Match ME; Millan C; Pergolizzi R
J Med Virol; 1996 Aug; 49(4):303-10. PubMed ID: 8877763
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Flandre P; Descamps D; Joly V; Meiffrédy V; Tamalet C; Izopet J; Aboulker JP; Brun-Vézinet F
Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
[TBL] [Abstract][Full Text] [Related]
4. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
[TBL] [Abstract][Full Text] [Related]
5. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
6. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
7. [Zidovudine plus didanosine in HIV infected asymptomatic patients previously treated with zidovudine].
López-Martínez C; Guarner J; Magis-Rodríguez C; Uribe-Zúñiga P; del Río-Chiriboga C
Rev Invest Clin; 1998; 50(4):335-9. PubMed ID: 9830323
[TBL] [Abstract][Full Text] [Related]
8. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
Raboud JM; Montaner JS; Rae S; Kahn J; Hammer SM; Katzenstein DA; Pavia A; Dolin R; Hughes MD; Cross A; Beltangady M; Gatell J; Dunkle L; Smaldone L
Antivir Ther; 1997 Dec; 2(4):237-47. PubMed ID: 11327443
[TBL] [Abstract][Full Text] [Related]
10. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
Kozal MJ; Kroodsma K; Winters MA; Shafer RW; Efron B; Katzenstein DA; Merigan TC
Ann Intern Med; 1994 Aug; 121(4):263-8. PubMed ID: 7518658
[TBL] [Abstract][Full Text] [Related]
11. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
12. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
[TBL] [Abstract][Full Text] [Related]
13. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
Marcelin AG; Flandre P; Furco A; Wirden M; Molina JM; Calvez V;
Antivir Ther; 2006; 11(6):693-9. PubMed ID: 17310813
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
15. Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children.
Palumbo PE; Raskino C; Fiscus S; Pahwa S; Schutzbank T; Spector SA; Baker CJ; Englund JA
J Infect Dis; 1999 Mar; 179(3):576-83. PubMed ID: 9952363
[TBL] [Abstract][Full Text] [Related]
16. Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapy.
Falkensammer B; El Attal R; Müllauer B; Sarcletti M; Parson W; Dierich MP; Stoiber H
Eur J Med Res; 2002 Sep; 7(9):379-86. PubMed ID: 12435615
[TBL] [Abstract][Full Text] [Related]
17. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
18. [Resistance of human immunodeficiency virus (HIV) to zidovudine. Genotypic analysis in strains isolated from Chilean patients].
Vial PA; Vial C; Abarca K; Noriega M; Jiménez G; Labarca J; Gasep J; Palacios O; Pérez C; Acuña G
Rev Med Chil; 1998 Jan; 126(1):17-26. PubMed ID: 9629750
[TBL] [Abstract][Full Text] [Related]
19. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
Mildvan D; Spritzler J; Grossberg SE; Fahey JL; Johnston DM; Schock BR; Kagan J
Clin Infect Dis; 2005 Mar; 40(6):853-8. PubMed ID: 15736019
[TBL] [Abstract][Full Text] [Related]
20. Effect of combined zidovudine and didanosine therapy in early asymptomatic primary HIV-1 infection.
Khajotia RR; Feigley CE; Lee E; Gu J
AIDS; 1998 Jan; 12(2):222-4. PubMed ID: 9468376
[No Abstract] [Full Text] [Related]
[Next] [New Search]
